Rosetta Genomics Reports Second Quarter 2008 Financi...(ly the gold standard of treatment for pa...)

ovarian cancer. However, approximately 20-25% of patients do not

respond to platinum-based chemotherapy and will require additional

second-line treatment. Furthermore, research suggests that

administering platinum-based treatment to patients who subsequently do

not respond to it may actually hinder their response to the second-line

treatment as well. Rosetta Genomics has identified unique microRNA

biomarkers that may assist in identifying ovarian cancer patients

expected to be resistant to platinum-based chemotherapy.

- Predicting risk of gastric cancer recurrence - Recurrence

after curative resection for gastric cancer is high and is estimated

to occur in 80% of patients. This test is being developed to use

microRNA biomarkers to predict the risk of recurrence for

non-metastatic patients after resection of the primary tumor.

- Differentiating small from non-small cell lung cancer - An

estimated 220,000(1) patients are diagnosed with lung cancer each year

in the U.S. alone. Before a patient begins lung cancer treatment, an

experienced lung cancer pathologist must review the pathologic

material. This is critical because small cell lung cancer, which is

generally not treated surgically, can be confused on microscopic

examination with non-small cell carcinoma(2). Rosetta Genomics has

identified unique microRNA biomarkers that may be used to differentiate

small from non-small cell lung cancers.

- Biomarker Discovery - identified microRNA biomarkers in the

serum of colon cancer patients which may serve as the basis for a

future blood-based test for colon cancer.

Corporate Development

- Completed the acquisition of Parkway Clinical Laboratories

Inc., a privately-held company owning a CLIA-certified lab lo
'/>"/>